Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
“AstraZeneca’s has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval following a Priority Review by the Food and Drug Administration (FDA) was based on the results from the FLAURA2 Phase III trial published in The New England Journal of Medicine. Tagrisso with the addition of chemotherapy reduced the risk of disease progression or death by 38% compared to Tagrisso monotherapy which is the 1st-line global standard of care (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.49-0.79; p<0.0001). Median progression-free survival (PFS) by investigator assessment was 25.5 months for patients treated with Tagrisso plus chemotherapy, an 8.8-month improvement versus Tagrisso monotherapy (16.7 months).”
Risk-based lung cancer screening in heavy smokers: a benefit–harm and cost-effectiveness modeling study
“Risk-based screening strategies are more efficient in reducing lung cancer deaths and gaining life years compared to the status quo strategy. Risk-stratified screening intervals can potentially balance long-term benefit–harm trade-offs and improve the cost-effectiveness of lung cancer screenings.”
FDA Accepts Dato-DXd Application for Non-Small Cell Lung Cancer
“The BLA for Dato-DXd, a TROP2-directed ADC, in previously treated, advanced, nonsquamous NSCLC has been accepted by the FDA, and a PDUFA target action date is anticipated in the fourth quarter of 2024.”
Reflex Molecular Testing May Enhance Targeted Therapy Benefit in Early-Stage Lung Cancer
“Efforts to standardize and implement reflex testing for biomarkers in early-stage non–small cell lung cancer could allow for earlier identification of appropriate targeted therapies that may be used in treatment, thereby improving patient outcomes, according to Jobelle Baldonado, MD, who adds that it is important for surgical oncologists to stay up to date on the development of targeted agents in lung cancer so they can best treat patients presenting with recurrent disease.”
Work-Related Respirable Crystalline Silica Exposure and Lung Cancer Risk
“Prevention measures should be taken to protect workers who are exposed to respirable crystalline silica (RCS) from lung cancer risk. Researchers assessed a systemic review of 20 studies found using the PubMed database and an online search of RCS limits set by institutional organizations. They sought to determine the cutoff points that could affect risk of mortality or incidence of lung cancer from occupational RCS exposure.”
Osimertinib Yields Activity, Manageable Toxicity in Metastatic EGFR+ NSCLC
“Treatment with osimertinib (Tagrisso) demonstrated clinical activity and a manageable safety profile among patients with metastatic non–small cell lung cancer (NSCLC) harboring EGFR mutations outside of exon 20 insertion mutations, according to findings from the phase 2 UNICORN trial (jRCTs071200002) published in JAMA Oncology.”
‘Help is right here’: Roswell Park brings lung cancer screening to people who need it
“Eddy is Roswell Park Comprehensive Cancer Center’s new mobile lung cancer screening unit – the size of a tractor-trailer – and its mission is in its name: “Early Detection Driven to You.”
Kentucky rises to No. 2 in the nation in screening for lung cancer, which lowers the chances that the disease will be fatal
“Dr. Tony Stumbo’s heart sank after the doctor shared his mother’s chest X-ray. “I remember that drive home, bringing her back home, and we basically cried,” said the internal medicine physician, who had started practicing in Eastern Kentucky near his childhood home in Floyd County shortly before his mother began feeling ill. “Nobody wants to get told they’ve got inoperable lung cancer. I cried because I knew what this meant for her.” Now Stumbo, whose mother died the following year, in 1997, is among a group of Kentucky clinicians and researchers determined to rewrite the script for other families by promoting training and boosting awareness about early detection in the state with the highest lung cancer death rate.”
Study Finds New Inhalable Therapy is a Big Step Forward in Lung Cancer Research
“Newswise — Lung cancer is one of the most common cancers and has one of the lowest survival rates in the world. Cytokines, which are small signaling proteins, such as interleukin-12 (IL-12), have demonstrated considerable potential as robust tumor suppressors. However, their applications are limited due to a multitude of severe side effects.”
Video:
Doctors warn of rise in lung cancer among non-smokers
“One Triad woman was diagnosed at 30 years old. There are three warning signs that you should see a doctor.”
Treatment-Specific Biomarkers, Future of Research for Lung Cancer with Jonathan Spicer, MD, PhD
“In this Lungcast segment, Spicer spoke on several treatment-specific biomarkers for lung cancer and discussed the future of lung cancer therapy.”
